AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today its financial results for the third quarter ended September 30, 2007. During the quarter, the Company used cash, cash equivalents and short-term investments of $6.0 million. Introgen’s cash, cash equivalents, short-term investments and marketable securities were $38.1 million at September 30, 2007.
